On this page ▾
Today's prices ask more of Cipla than of Dr Reddy's.
At current prices, buyers of Cipla are assuming about 2% growth against 7% in its own record; for Dr Reddy's it is 0% against 13%. That shows which share needs more to go right — not which is cheaper. How far each trades from its estimated fair value is in the full valuations.
- Valuation method: both on discounted cash flow.
- Size: the two are worth roughly the same on the stock market.
- Record: Dr Reddy's has grown revenue faster: Cipla compounded at about 8% a year (FY2018–FY2026) and Dr Reddy's at about 11% (FY2018–FY2026).
- What to watch: complex us generics at Cipla; replacing revlimid at Dr Reddy's.
| Cipla | Dr Reddy's | |
|---|---|---|
| Price | ₹1,394 | ₹1,378 |
| Market cap | ₹1.13L Cr | ₹1.15L Cr |
| P/E | 38.9 | 41.1 |
| P/B | 3.27 | 3.04 |
| Fair value 🔒 sign in | ₹0,000 | ₹0,000 |
| Upside 🔒 sign in | +00% | +00% |
| Valued on | Discounted cash flow | Discounted cash flow |
01Two businesses
Ninety years of affordable medicine
Cipla was founded in 1935 by Khwaja Abdul Hamied and became known worldwide for low-cost HIV medicines in the early 2000s. Today it is one of India's largest pharmaceutical companies, with strong positions in India, South Africa and the US.
A Hyderabad generics maker with a global footprint
Dr Reddy's Laboratories was founded in Hyderabad in 1984 by Dr K. Anji Reddy. It makes generic medicines for the US, India, Russia and other emerging markets, and active pharmaceutical ingredients that it sells to other drugmakers.
02The records side by side
Dr Reddy's has grown revenue faster: Cipla compounded at about 8% a year (FY2018–FY2026) and Dr Reddy's at about 11% (FY2018–FY2026). By revenue the two are of broadly similar size. Cipla kept 13.7% of revenue as net profit in FY2026; Dr Reddy's kept 12.3% of revenue as net profit in FY2026.
Full ten-year tables and charts are on each company's page: Cipla · Dr Reddy's.
03What each price assumes
Work backwards from each share price and you can see what buyers are taking for granted — the rate each company must sustain to justify what it costs, against what its own record supports.
04What decides each one's value
- Complex US genericsInhalers and other hard-to-make products face less competition than simple pills.
- India branded businessSteady, cash-rich and growing with the domestic market.
- Replacing RevlimidNew US launches and other markets need to fill the gap left by one very profitable product.
- US generic pricingPrices for older generics keep falling, so the pipeline has to keep moving.
05What could go wrong
- FDA complianceInspection problems at key plants have delayed launches before.
- US price erosionGeneric prices fall as competitors enter.
- FDA inspectionsAdverse findings at a plant can block US approvals and shipments.
- Pipeline delaysLate approvals push out the launches that replace lost profit.
06Which is better value?
Sign in free to see which trades further below its worth
- ✓Both fair values per share — each on the method that fits the business
- ✓Every step of both workings — growth, margins and cost of capital, with sources
- ✓Bull, base and bear cases — for each company
- ✓Downloadable reports — the full write-up for each, yours to keep
08Questions people ask
Is Cipla or Dr Reddy's better value?
That turns on how far each share trades from its estimated fair value. Both figures, with every step of the working, are in the full valuations, free to view once you sign in. On the public numbers, Cipla trades at 38.9 times earnings and 3.27 times book value, and Dr Reddy's at 41.1 times earnings and 3.04 times book value — but multiples alone mislead when two businesses work differently, which is why each is valued on the method that fits it.
What is the difference between Cipla and Dr Reddy's?
Cipla was founded in 1935 by Khwaja Abdul Hamied and became known worldwide for low-cost HIV medicines in the early 2000s. Dr Reddy's Laboratories was founded in Hyderabad in 1984 by Dr K.
Are Cipla and Dr Reddy's valued the same way?
Yes — both on discounted cash flow, so their workings compare like for like.
What does today's price assume for Cipla and Dr Reddy's?
Worked backwards from the share price, Cipla needs about 2% growth and Dr Reddy's about 0% growth, against 7% and 13% in their own records.